Simon Dew

Simon Dew was appointed Chief Business Officer in November 2022.

Simon joined ReNeuron from Mereo BioPharma Plc, where he was Vice President Business and Corporate Development. Prior to that he was Vice President Business Development at Evox Therapeutics, where he was responsible for several transformative deals in the exosome space.

Simon has over 25 years’ experience in pharmaceutical Business Development, Corporate Development and Corporate Strategy, responsible for multiple BD&L and M&A transactions.

Over his career, he has held senior leadership roles in Pharma and Biotech, including VP Corporate Strategy at Gyroscope Therapeutics, prior to its acquisition by Novartis and as SVP Corporate Strategy and Business Development as Astellas Pharmaceuticals, as well as operational leadership roles in Quintiles (IQVIA), Parexel, Phytopharm plc and GSK/SB, in Europe and in international markets

He is currently on the Business Development Board of Sunstone Capital a Danish Venture Capital Company.

He holds a degree in Pharmacy and is a member of the Royal Pharmaceutical Society of Great Britain